HGH Fragment 176-191

Laboratory Handling Directions

• Store at controlled room temperature (15–25°C / 59–77°F)
• Protect from light and moisture during storage
• Use aseptic technique when handling compound
• Reconstitute with bacteriostatic water as appropriate
• Once reconstituted, refrigerate at 2–8°C (36–46°F)
• Document all handling procedures per laboratory protocols
  

HGH Fragment 176-191 research peptide primarily targets adipose tissue through activation of beta-3 adrenergic receptors (β3-AR), particularly in white and brown fat depots, leading to elevated intracellular cAMP levels that activate protein kinase A (PKA) and initiate downstream lipolytic cascades. Furthermore, this process enhances hormone-sensitive lipase activity to promote fatty acid release and oxidation, while inhibiting lipogenesis to reduce triglyceride accumulation in adipocytes. Additionally, laboratory models indicate potential mitochondrial uncoupling and increased thermogenesis in skeletal muscle, contributing to greater energy expenditure without impacting insulin sensitivity or IGF-1 production. These selective actions, observed in rodent adipose assays and metabolic studies, support observed reductions in fat mass, with recent research underscoring its reassuring profile for focused lipid pathway modulation and metabolic efficiency in obesity and energy balance models.

Research Applications

• Adipocyte signaling pathway analysis
• Lipolysis mechanism research
• Fragment peptide efficacy studies
• Metabolic pathway interaction evaluation
• Selective receptor activity investigations
  

Scientific References

• Ng FM et al. J Mol Endocrinol. 2000;25(3):287-298
• Heffernan MA et al. Mol Cell Endocrinol. 2001;171(1-2):143-152
• Ridderstrale M et al. Mol Cell Endocrinol. 2002;192(1-2):147-157
• Stier CT et al. Curr Pharm Des. 2003;9(17):1399-1410